Biomarker Identified Potential Prostate Cancer Treatment Benefit
Researchers found that a specific tumor subtype may help predict who benefits most from androgen deprivation therapy.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Should genetic screening be a standard requirement to determine the necessity of cancer therapy?
Scientists have identified PAM50 luminal B status as a key predictor for how well prostate cancer patients respond to androgen deprivation therapy. This finding, based on a secondary analysis of the NRG/RTOG 0534 SPPORT trial, could help tailor treatment plans for patients.
Why it matters
By identifying which tumors are more responsive to specific hormone therapies, clinicians may be better equipped to personalize treatment plans and improve long-term outcomes for those at higher risk. This work aims to shift prostate cancer care toward more precise, biology-driven decisions.
This analysis of 709 prostatectomy samples from the NRG/RTOG 0534 SPPORT trial identified that PAM50 luminal B status is associated with higher hazard ratios for failure and metastasis compared to non-luminal B subtypes.
The players
NRG/RTOG 0534 SPPORT
A clinical trial investigating the benefits of adding androgen deprivation therapy and pelvic lymph node radiation to prostate bed radiation.
ASTRO
The American Society for Radiation Oncology, which hosts an annual meeting focused on clinical research and advancements in radiation medicine.
The details
PAM50 profiling categorizes tumor samples based on gene expression patterns, specifically distinguishing luminal B tumors that show increased proliferative activity and androgen receptor signaling. The underlying trial compared three approaches: radiation therapy alone, radiation combined with short-term androgen deprivation therapy, and a triple approach including pelvic lymph node radiation. The luminal B subtype appears to track with specific biological behaviors that influence how tumors respond to hormonal suppression.
Timeline
September 26-30, 2026: Researchers presented the study findings at the ASTRO annual meeting in Boston.
Health Landscape
This research builds upon the NRG/RTOG 0534 SPPORT trial by integrating genomic profiling into standard post-prostatectomy care models. It highlights the growing movement to use molecular biomarkers to refine treatment intensity for patients after prostate surgery.
If you are managing a prostate cancer diagnosis, it is worth discussing with your physician whether genomic testing or biomarker profiling is appropriate for your specific clinical situation. These tests may help your medical team determine if adding hormone therapy could provide a measurable benefit for your long-term health.
The takeaway
Genomic profiling is offering new ways to predict how prostate cancer will respond to hormonal treatments. Ask your oncologist if biomarker testing might help clarify your personal prognosis or treatment options.
Further reading
For more on evolving research in this field, visit our section on Cancer.
Source note: This article includes information reported by Oncology Nurse Advisor.
Live Poll
Should genetic screening be a standard requirement to determine the necessity of cancer therapy?
